AKT1 and breast cancer: In terms of mechanism, AIL inhibits the RANKL and IL-1β secretion in the CM or the BC cells by upregulating FOXP3 in BC cells and also prevents the differentiation and functioning of the osteoclasts induced by the BC cell supernatant by inhibiting the NF-κB, PI3K/AKT, and MAPK signaling pathways (Figure 8).